TPWA
FATE icon

Twin Peaks Wealth Advisors’s Fate Therapeutics FATE Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-200
Closed -$240 – 883
2026
Q1 		$240 Buy
+200
New +$244 ﹤0.01% 2148
2025
Q3 		– Sell
-200
Closed -$187 – 806
2025
Q2 		$187 Buy
+200
New +$232 ﹤0.01% 2043

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Twin Peaks Wealth Advisors's FATE Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Fate Therapeutics (FATE) in Q2 2026, closing a stake of 200 shares — an estimated $240 sold.

Twin Peaks Wealth Advisors first reported a position in FATE in Q2 2025 and held it in 2 quarters. The position peaked at $240 in Q1 2026. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Fate Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 200 Fate Therapeutics shares in Q2 2026, an estimated $240.
  • Twin Peaks Wealth Advisors first reported a position in Fate Therapeutics in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Fate Therapeutics position peaked at $240 in Q1 2026.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.